From USFDA
Glenmark Pharmaceuticals announced that Glenmark Pharmaceuticals Inc. USA has been granted final approval by the United States Food & Drug Administration for Voriconazole Tablets, 50 mg and 200 mg, the therapeutic equivalent of Vfend Tablets, 50 mg and 200 mg of Prism C.V. (Prism).According to IMS Health sales data for the 12 month period ending July 2015, the Vfend market achieved annual sales of approximately USD 91.4 million.
Powered by Capital Market - Live News
